ALZpath Press Releases

ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor

March 25th, 2025

ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

March 18th, 2025

ALZpath Appoints Mike Banville as CEO

January 27th, 2025

Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research

November 18th, 2024

ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024

October 30th, 2024

New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis

July 29th, 2024

ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease

July 15th, 2024

ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer

July 9th, 2024

ALZpath Partners with Roche to Provide pTau217 Antibody for Alzheimer's Diagnostic Blood Test

June 10th, 2024

Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research

February 29th, 2024

New Study in JAMA Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test

JANUARY 22, 2024

ALZpath Announces Partnership with ADDF for Clinical Alzheimer's Diagnostic Launch

JULY 18, 2023

ALZpath Announces Novel Scalable Assay for pTau217

NOVEMBER 28, 2022

Media

Media Inquiries: media@alzpath.bio